UY36326A - N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b - Google Patents

N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b

Info

Publication number
UY36326A
UY36326A UY0001036326A UY36326A UY36326A UY 36326 A UY36326 A UY 36326A UY 0001036326 A UY0001036326 A UY 0001036326A UY 36326 A UY36326 A UY 36326A UY 36326 A UY36326 A UY 36326A
Authority
UY
Uruguay
Prior art keywords
nr2b
negative
oxiaril
alquilaril
ciclopenta
Prior art date
Application number
UY0001036326A
Other languages
English (en)
Spanish (es)
Inventor
David R Anderson
Robert A Volkmann
Frank S Menniti
Original Assignee
Mnemosyne Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55581945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY36326(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mnemosyne Pharmaceuticals Inc filed Critical Mnemosyne Pharmaceuticals Inc
Publication of UY36326A publication Critical patent/UY36326A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UY0001036326A 2014-09-26 2015-09-25 N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b UY36326A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462056284P 2014-09-26 2014-09-26

Publications (1)

Publication Number Publication Date
UY36326A true UY36326A (es) 2016-04-29

Family

ID=55581945

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036326A UY36326A (es) 2014-09-26 2015-09-25 N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b

Country Status (40)

Country Link
US (4) US10239835B2 (cg-RX-API-DMAC7.html)
EP (4) EP3974420B1 (cg-RX-API-DMAC7.html)
JP (5) JP6473227B2 (cg-RX-API-DMAC7.html)
KR (1) KR102479356B1 (cg-RX-API-DMAC7.html)
CN (1) CN106795111B (cg-RX-API-DMAC7.html)
AP (1) AP2017009832A0 (cg-RX-API-DMAC7.html)
AR (1) AR103199A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015320721B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017006093B1 (cg-RX-API-DMAC7.html)
CA (1) CA2962569C (cg-RX-API-DMAC7.html)
CL (1) CL2017000474A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017002494A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170114A (cg-RX-API-DMAC7.html)
CU (1) CU24482B1 (cg-RX-API-DMAC7.html)
CY (1) CY1123533T1 (cg-RX-API-DMAC7.html)
DK (1) DK3197868T3 (cg-RX-API-DMAC7.html)
EA (1) EA034937B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17025302A (cg-RX-API-DMAC7.html)
ES (3) ES2911004T3 (cg-RX-API-DMAC7.html)
GT (1) GT201700062A (cg-RX-API-DMAC7.html)
HR (1) HRP20200959T1 (cg-RX-API-DMAC7.html)
HU (1) HUE049698T2 (cg-RX-API-DMAC7.html)
IL (1) IL250909B (cg-RX-API-DMAC7.html)
JO (1) JO3579B1 (cg-RX-API-DMAC7.html)
LT (1) LT3197868T (cg-RX-API-DMAC7.html)
MX (1) MX374657B (cg-RX-API-DMAC7.html)
MY (1) MY182342A (cg-RX-API-DMAC7.html)
NZ (1) NZ729569A (cg-RX-API-DMAC7.html)
PE (1) PE20170893A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500513A1 (cg-RX-API-DMAC7.html)
PL (1) PL3197868T3 (cg-RX-API-DMAC7.html)
PT (1) PT3197868T (cg-RX-API-DMAC7.html)
RS (1) RS60497B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201702023QA (cg-RX-API-DMAC7.html)
SI (1) SI3197868T1 (cg-RX-API-DMAC7.html)
TN (1) TN2017000076A1 (cg-RX-API-DMAC7.html)
TW (1) TWI687407B (cg-RX-API-DMAC7.html)
UY (1) UY36326A (cg-RX-API-DMAC7.html)
WO (1) WO2016049165A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201701061B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
CA3079617A1 (en) 2017-10-20 2019-04-25 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
WO2019089676A1 (en) 2017-10-31 2019-05-09 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
CA3090130A1 (en) 2018-02-02 2019-08-08 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
SG11202008113RA (en) 2018-03-05 2020-09-29 Arcus Biosciences Inc Arginase inhibitors
EP3980420B1 (en) 2019-06-04 2023-04-19 Boehringer Ingelheim International GmbH Imidazopyrazine derivatives and the use thereof as medicament
EP3980401A1 (en) * 2019-06-04 2022-04-13 Boehringer Ingelheim International GmbH Purine derivatives, as nr2b negative modulators and the use thereof as medicament, in particular for treating depressive disorders
CN111481543A (zh) * 2020-05-21 2020-08-04 苏州健雄职业技术学院 Nr2b负变构调节剂联合gaba受体调节剂在制备治疗阿尔兹海默症的药物中的用途
CN116744922A (zh) * 2020-12-04 2023-09-12 诺华股份有限公司 Nr2b-nmda受体nam在治疗抑郁症中的剂量方案
IL303357A (en) * 2020-12-04 2023-08-01 Novartis Ag Dosage regimen for a nr2b-nmda receptor nam for the treatment of depression
JP2021058765A (ja) * 2021-01-19 2021-04-15 株式会社藤商事 遊技機
EP4313042A4 (en) * 2021-03-26 2025-01-15 Novartis AG NEW CYCLOPENTA[C PYRROL NEGATIVE ALLOSTERIC MODULATORS OF NR2B
CA3212203A1 (en) * 2021-03-26 2022-09-29 Novartis Ag Novel cyclopenta[c]pyrrol negative allosteric modulators of nr2b
JP2025518778A (ja) 2022-06-02 2025-06-19 ノバルティス アーゲー 鬱病性障害の治療に使用するためのオンファスプロジルの皮下投与及び投与方法
EP4649143A1 (en) 2023-01-12 2025-11-19 Novartis AG Engineered ketoreductase polypeptides
WO2025120013A1 (en) 2023-12-06 2025-06-12 Novartis Ag Compositions and methods for treating depression disorders

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532243A (en) 1992-02-14 1996-07-02 The Dupont Merck Pharmaceutical Company Antipsychotic nitrogen-containing bicyclic compounds
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
DE4341403A1 (de) * 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
US5726172A (en) * 1996-01-16 1998-03-10 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
JP4845873B2 (ja) 2004-03-03 2011-12-28 ケモセントリックス インコーポレーティッド 二環式および架橋した窒素複素環
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
WO2005121145A2 (en) 2004-06-09 2005-12-22 F. Hoffmann-La Roche Ag Octahydro-pyrrolo[3,4-c] derivatives and their use as antiviral compounds
JP2008507543A (ja) 2004-07-22 2008-03-13 グラクソ グループ リミテッド 抗細菌剤
HUP0401523A3 (en) 2004-07-29 2007-05-02 Richter Gedeon Vegyeszet Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
AU2006236625A1 (en) 2005-04-19 2006-10-26 Merck & Co., Inc. N-alkyl-azacycloalkyl NMDA/NR2B antagonists
EP1849772A1 (en) 2006-04-28 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Bicyclic tetrahydropyrrole compounds
WO2007128458A1 (en) 2006-04-28 2007-11-15 Laboratorios Del Dr. Esteve, S.A. Bicyclic tetrahydropyrrole compounds
TW200845977A (en) 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
EP2217596B8 (en) 2007-10-22 2013-11-20 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
WO2009094866A1 (en) 2008-01-23 2009-08-06 Shanghai Hengrui Pharmaceutical Co., Ltd. Dicycloazaalkane derivates, preparation processes and medical uses thereof
EP2378885A4 (en) 2008-12-12 2013-01-02 Univ Vanderbilt 3.3.0 BICYCLIC GLYT1 INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
FR2945533B1 (fr) 2009-05-12 2011-05-27 Sanofi Aventis Derives de cyclopenta°c!pyrrolyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
FR2945534B1 (fr) * 2009-05-12 2012-11-16 Sanofi Aventis DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
WO2011085170A1 (en) 2010-01-07 2011-07-14 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
US8796470B2 (en) 2010-05-25 2014-08-05 Abbvie Inc. Substituted octahydrocyclopenta[c]pyrroles as calcium channel modulators
CN102432598A (zh) * 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
FR2974729B1 (fr) 2011-05-02 2013-04-19 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
US8501768B2 (en) 2011-05-17 2013-08-06 Hoffmann-La Roche Inc. Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
JO3611B1 (ar) * 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
SI2796460T1 (sl) 2011-12-21 2018-10-30 Jiangsu Hengrui Medicine Co. Ltd Pirolni šestčlenski derivat heteroarilnega obroča, postopek priprave zanj in medicinske uporabe le-tega
ES2753163T3 (es) * 2012-09-25 2020-04-07 Hoffmann La Roche Derivados de hexahidropirrolo[3,4-c]pirrol y compuestos relacionados como inhibidores de la autotaxina (ATX) y como inhibidores de la producción de ácido lisofosfatídico (LPA) para tratar, por ejemplo, enfermedades renales
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
US9418332B2 (en) 2013-08-16 2016-08-16 Qualcomm Incorporated Post ghost plasticity
EP3461827B1 (en) * 2013-09-26 2022-02-23 Cadent Therapeutics, Inc. Selective octahydro-cyclopenta[c]pyrrole negative modulators of nr2b
SG11201607839UA (en) 2014-03-26 2016-10-28 Hoffmann La Roche Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول

Also Published As

Publication number Publication date
EP3197868B1 (en) 2020-04-15
HRP20200959T1 (hr) 2020-10-02
TW201625528A (zh) 2016-07-16
TWI687407B (zh) 2020-03-11
EA201790713A1 (ru) 2017-07-31
CA2962569C (en) 2023-09-19
PL3197868T3 (pl) 2020-11-02
PE20170893A1 (es) 2017-07-12
MX374657B (es) 2025-03-06
JP2019077713A (ja) 2019-05-23
EP3197868A4 (en) 2018-04-25
WO2016049165A1 (en) 2016-03-31
EP3197868A1 (en) 2017-08-02
SI3197868T1 (sl) 2020-10-30
ES2791327T3 (es) 2020-11-03
CN106795111B (zh) 2020-04-07
PH12017500513A1 (en) 2017-08-07
JP2023052515A (ja) 2023-04-11
AU2015320721A1 (en) 2017-03-30
BR112017006093B1 (pt) 2023-03-21
EP3683207B1 (en) 2021-12-29
KR20170063599A (ko) 2017-06-08
EA034937B1 (ru) 2020-04-08
CN106795111A (zh) 2017-05-31
US12145909B2 (en) 2024-11-19
US10781174B2 (en) 2020-09-22
PT3197868T (pt) 2020-05-21
ES2911004T3 (es) 2022-05-17
SG11201702023QA (en) 2017-04-27
EP3974420A1 (en) 2022-03-30
CL2017000474A1 (es) 2017-08-18
IL250909B (en) 2019-06-30
EP3683207A1 (en) 2020-07-22
JP7612722B2 (ja) 2025-01-14
MX2017003940A (es) 2018-03-01
MY182342A (en) 2021-01-20
AR103199A1 (es) 2017-04-26
JP6772307B2 (ja) 2020-10-21
CY1123533T1 (el) 2022-03-24
ECSP17025302A (es) 2018-11-30
US20190152912A1 (en) 2019-05-23
JP6473227B2 (ja) 2019-02-20
TN2017000076A1 (en) 2018-07-04
JP2017528502A (ja) 2017-09-28
JP2025060835A (ja) 2025-04-10
GT201700062A (es) 2019-09-30
HUE049698T2 (hu) 2020-10-28
CU20170037A7 (es) 2017-08-08
ES2956546T3 (es) 2023-12-22
CR20170114A (es) 2017-08-21
DK3197868T3 (da) 2020-06-22
JP2021006554A (ja) 2021-01-21
CA2962569A1 (en) 2016-03-31
JO3579B1 (ar) 2020-07-05
NZ729569A (en) 2019-06-28
BR112017006093A2 (pt) 2017-12-19
AP2017009832A0 (en) 2017-03-31
LT3197868T (lt) 2020-09-10
AU2015320721B2 (en) 2020-01-30
JP7216060B2 (ja) 2023-01-31
CU24482B1 (es) 2020-03-04
US20220274925A1 (en) 2022-09-01
US20200369610A1 (en) 2020-11-26
US20180111902A1 (en) 2018-04-26
KR102479356B1 (ko) 2022-12-19
US10239835B2 (en) 2019-03-26
RS60497B1 (sr) 2020-08-31
ZA201701061B (en) 2019-07-31
EP3974420B1 (en) 2023-08-16
EP4282412A3 (en) 2024-01-17
EP4282412A2 (en) 2023-11-29
CO2017002494A2 (es) 2017-08-31
IL250909A0 (en) 2017-04-30

Similar Documents

Publication Publication Date Title
UY36326A (es) N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b
CR20160212A (es) Composiciones y métodos para modular los receptores x farnesoides
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
MX2020001360A (es) Macrociclos de diarilo como moduladores de la proteina quinasa.
MX2017014375A (es) Moduladores del ccr2.
UY33497A (es) Derivados de espiro-piperidina como moduladores s1p
CR20150571A (es) Compuestos y composiciones terapéuticos
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
ECSP16025201A (es) Profármacos de amidas de piridona útiles como moduladores de canales de sodio
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
CU20130094A7 (es) Moduladores de la vía del complemento
PE20151788A1 (es) Inhibidores de bromodominios tetraciclicos
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
EA201790785A1 (ru) Производные тетрагидроизохинолина
GT201200004A (es) Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria
MX382869B (es) Derivados de 2-anilinopirimidina sustituida como moduladores de egfr.
EA201590881A1 (ru) Терапевтические соединения и композиции и их использование в качестве модуляторов пк-m2
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
SV2017005381A (es) Compuestos de imidazopiridazina
CU20160140A7 (es) CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA
MX2022006862A (es) Inhibidores duales de magl y faah.
CY1122403T1 (el) Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης
CO2017009989A2 (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda
ECSP16074207A (es) Pirazinas moduladoras de gpr6

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20231003